Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Cash from Investing Activities (2022 - 2025)

Historic Cash from Investing Activities for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to -$58000.0.

  • Axsome Therapeutics' Cash from Investing Activities rose 3555.56% to -$58000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$439000.0, marking a year-over-year decrease of 7773.28%. This contributed to the annual value of -$270000.0 for FY2024, which is 5360.82% up from last year.
  • Axsome Therapeutics' Cash from Investing Activities amounted to -$58000.0 in Q3 2025, which was up 3555.56% from -$13000.0 recorded in Q2 2025.
  • Axsome Therapeutics' 5-year Cash from Investing Activities high stood at -$7000.0 for Q4 2023, and its period low was -$53.2 million during Q2 2022.
  • For the 4-year period, Axsome Therapeutics' Cash from Investing Activities averaged around -$3.7 million, with its median value being -$90000.0 (2024).
  • Over the last 5 years, Axsome Therapeutics' Cash from Investing Activities had its largest YoY gain of 9975.02% in 2023, and its largest YoY loss of 46212.12% in 2023.
  • Axsome Therapeutics' Cash from Investing Activities (Quarter) stood at -$181000.0 in 2022, then skyrocketed by 96.13% to -$7000.0 in 2023, then crashed by 328.57% to -$30000.0 in 2024, then plummeted by 93.33% to -$58000.0 in 2025.
  • Its Cash from Investing Activities stands at -$58000.0 for Q3 2025, versus -$13000.0 for Q2 2025 and -$338000.0 for Q1 2025.